Q-omics provides the consensus-scored TMEM30A profile across patient tissues and cancer cell-line models. TMEM30A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TMEM30A is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TMEM30A protein abundance shows 31,676 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where TMEM30A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM30A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM30A survival associations across molecular data types. TMEM30A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM30A RNA expression–survival associations across cancer types. High TMEM30A expression shows unfavorable associations in KIRP, CESC and ACC, but favorable associations in SKCM, LGG and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TMEM30A RNA expression.
This table summarizes TMEM30A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM30A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM30A shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, BLCA, ESCA and STAD. The HNSC box plot shows higher TMEM30A RNA expression in tumor versus normal tissue (log2 FC = +1.121, t-test p < 0.001).
This table shows molecular features associated with TMEM30A in patient tissues and cancer cell lines. In patient samples, TMEM30A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM30A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
